Delivery Order SPE2DR25D1053-SPE2DR26FV088
- Not listed
- The Defense Logistics Agency awarded a $11,948.21 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on December 10, 2025, with an ultimate completion date of December 11, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a single delivery order under AmerisourceBergen's broader pharmaceutical supply agreement with the federal government. The product will be delivered to the company's corporate office...
- The Defense Logistics Agency awarded a $123,569.74 firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of RINVOQ ER 15 mg tablets (30-count units) on December 10, 2025, with completion scheduled for December 11, 2025. This is a competitively awarded, non-set-aside delivery order with performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $10,713.45 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on December 22, 2025, with completion scheduled for December 23, 2025. This non-competitive delivery order is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania. The award represents a continuation of the company's ongoing pharmaceutical supply relationship with the federal government's medical...
- The Defense Logistics Agency awarded a delivery order valued at $6,558.42 to AmerisourceBergen Drug Corp on December 8, 2025, for the supply of RINVOQ ER 15mg tablets (30-count supply). This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under open competition. The product will be delivered to AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, with an ultimate completion date of December 9, 2025. This delivery order is issued...
- The Defense Logistics Agency awarded a $26,987.87 firm fixed-price delivery order to AmerisourceBergen Drug Corp on November 28, 2025, for supply of RINVOQ ER 15 mg tablets (30-count units). This is a non-set-aside competitive award with an ultimate completion date of December 1, 2025. The delivery order is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This delivery order is issued under...
- The Defense Logistics Agency awarded a $49,188.15 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of RINVOQ ER 15MG tablets (30-count units) under contract number 4570137441. The contract was competitively awarded without set-aside designation and is scheduled for completion by December 3, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the performing location for this delivery order, leveraging its established role as a critical...
- The Defense Logistics Agency awarded a $14.3K firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count units) on December 23, 2025, with completion due by December 24, 2025. This non-set-aside award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The product will be supplied to the place of performance in Conshohocken,...
- The Defense Logistics Agency awarded a $28,730.55 firm fixed price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 27, 2025, with an ultimate completion date of August 28, 2025. This competitively awarded, non-set-aside contract is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's larger pharmaceutical supply relationship...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) with a ceiling value of $6,558.40. Issued on November 14, 2025, with an ultimate completion date of November 17, 2025, this firm fixed-price delivery order represents a competitively awarded, non-set-aside procurement. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a $7,492.02 firm fixed price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15mg tablets (30-count) on December 10, 2025, with completion scheduled for December 11, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger indefinite delivery vehicle with DLA Troop Support Medical. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery...
- SPE2DR25D1053Indefinite Delivery Contract
- SPE2DR25D1053-SPE2DR26FV088Delivery Order
The Defense Logistics Agency awarded a $10.77K delivery order to AmerisourceBergen Drug Corp on December 30, 2025, for RINVOQ ER 30 mg tablets (30-count units). This is a firm fixed-price delivery order with an ultimate completion date of December 31, 2025, representing a competitive award with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.99M through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply pharmaceuticals, medical supplies, vaccines, and specialty medications to support military healthcare programs worldwide. RINVOQ (upadacitinib) is a JAK inhibitor used in the treatment of rheumatoid arthritis and other inflammatory conditions, reflecting the company's role in providing critical pharmaceutical commodities across multiple therapeutic domains for the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.8k | 12/29/25 |